MVMDF (Mountain Valley MD Holdings) YoY EBITDA Growth: 50.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Mountain Valley MD Holdings YoY EBITDA Growth?

Mountain Valley MD Holdings MVMDF +3.64% YoY EBITDA Growth is 50.00% as of Mar. 2026. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Mountain Valley MD Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 50.00%.

Mountain Valley MD Holdings's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

Mountain Valley MD Holdings YoY EBITDA Growth Related Terms

Mountain Valley MD Holdings YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Mountain Valley MD Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mountain Valley MD Holdings YoY EBITDA Growth Chart

Mountain Valley MD Holdings Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
YoY EBITDA Growth
Get a 7-Day Free Trial 4.35 50.00 45.45 -16.67 28.57

Mountain Valley MD Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 50.00 0.00 50.00 50.00

Mountain Valley MD Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Mountain Valley MD Holdings's YoY EBITDA Growth for the fiscal year that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (A: Mar. 2026 )
=(EBITDA per Share (A: Mar. 2026 )-EBITDA per Share (A: Mar. 2025 ))/ | EBITDA per Share (A: Mar. 2025 ) |
=(-0.005--0.007)/ | -0.007 |
=28.57 %

Mountain Valley MD Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.001--0.002)/ | -0.002 |
=50.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 50.00% mean?
Mountain Valley MD Holdings (MVMDF) has a YoY EBITDA Growth of 50.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Mountain Valley MD Holdings and its competitors.
Is Mountain Valley MD Holdings' YoY EBITDA Growth too high?
Mountain Valley MD Holdings' current YoY EBITDA Growth is 50.00%.
How does Mountain Valley MD Holdings' YoY EBITDA Growth compare to ZTS?
Mountain Valley MD Holdings' YoY EBITDA Growth of 50.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Mountain Valley MD Holdings and its competitors. Mountain Valley MD Holdings's current YoY EBITDA Growth is 50.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mountain Valley MD Holdings stock overvalued right now?
Mountain Valley MD Holdings (MVMDF) has a current YoY EBITDA Growth of 50.00%. The current YoY EBITDA Growth is 50.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Mountain Valley MD Holdings (MVMDF), the current YoY EBITDA Growth is 50.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mountain Valley MD Holdings Business Description

Other Exchanges 20MP:GermanyMVMD:Canada
Address 260 Edgeley Boulevard, Unit 4, Vaughan, ON, CAN, L6K 3Y4
Mountain Valley MD Holdings Inc is a Canada-based company. The firm, along with its subsidiaries, is engaged in implementing its Quicksome oral delivery technologies across a variety of molecules in nutraceutical, vaccine, and pharmaceutical drug applications. The company actively invests in and collaborates on pioneering biotechnologies that have the potential to revolutionize the human health and wellness landscape, drive sustainable increases in plant yields and agricultural farming practices, and broadly support animal husbandry health. The Company is a biotech company focused on advancing solutions to optimize human, animal, and plant health.